** Shares of Clarity Pharmaceuticals CU6.AX fall 4.5% to A$1.815
** The pharma firm said it will now prioritise development of 64/67Cu-SAR -bis-PSMA for diagnostic and therapeutic applications in prostate cancer
** Jefferies cuts price target to A$4.70 from A$7, retains "buy" rating, based on net present value of co's late-stage pipeline
** Brokerage says it now assumes capital raise in FY26 to address cash reserves and R&D spend to decrease in FY25E
** Also revises Bis-PSMA PCa therapy take-up rate for prostate cancer rate to 5% from 9%
** Clarity stock up 57.1%, YTD
(Reporting by Kumar Tanishk in Bengaluru)
((Tanishk.Kumar@thomsonreuters.com; X: @thatstanishk;))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。